Advertisement

Foreword: changing the treatment paradigm for coronary artery disease

  • Caldwell B. Esselstyn Jr.
    Correspondence
    Address for reprints: Caldwell B. Esselstyn, Jr., MD, Department of General Surgery, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195
    Affiliations
    Department of General Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Search for articles by this author
      This supplement to The American Journal of Cardiology presents the proceedings of the Summit on Cholesterol and Coronary Disease: Second National Conference on Lipids in the Elimination and Prevention of Coronary Artery Disease presented by the Cleveland Clinic Foundation in cooperation with the Walt Disney Company in Lake Buena Vista, Florida, September 4–5, 1997.
      Figure thumbnail GR1
      Caldwell B. Esselstyn, Jr.Caldwell B. Esselstyn, Jr., MD
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. National Research Council (US) Committee on Diet and Health. Diet and health: implications for reducing chronic disease risk/Committee on Diet and Health, Food and Nutrition Board, Commission on Life Sciences, National Research Council, Washington, DC: National Academy Press, 1989.

        • Castelli W.
        From the desk of William P. Castelli, Medical Director, Framingham Cardiovascular Institute, Framingham, MA.
        Prevention. 1996; 48: 61-64
        • Temple N.J.
        • Burkitt D.P.
        Western Diseases—Their Dietary Prevention and Reversibility. Humana Press, Totowa, New Jersey1994
        • Chen J.
        • Campbell T.C.
        • Li J.
        • Peto R.
        Diet, Lifestyle, and Mortality in China. A Study of the Characteristics of 65 Chinese Counties. Oxford University Press, Cornell University Press, People’s Medical Publishing House, Oxford, UK; Ithaca, NY; Beijing, PRC1990
        • Berenson G.S.
        • Wattigney W.A.
        • Tracy R.E.
        • Newman III, W.P.
        • Srinivasan S.R.
        • Webber L.S.
        • Dalferes Jr, E.R.
        • Strong J.P.
        Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (The Bogalusa Heart Study).
        Am J Cardiol. 1992; 70: 851-858
        • Scandinavian Simvastatin Survival Study Group
        Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease.
        Lancet. 1994; 344: 1383-1389
        • Shepherd J.
        • Cobbe S.M.
        • Ford I.
        • Isles C.G.
        • Lorimer A.R.
        • Macfarlane P.W.
        • McKillop J.H.
        • Packard C.J.
        Prevention of CHD with pravastatin in men with hypercholesterolemia.
        N Engl J Med. 1995; 333: 1301-1307
        • Sacks F.M.
        • Pfeffer M.A.
        • Moye L.A.
        • Rouleau J.L.
        • Rutherford J.D.
        • Cole T.G.
        • Brown L.
        • Warnica J.W.
        • Arnold J.M.O.
        • Wun C.
        • Davis B.R.
        • Braunwald E.
        The effect of pravastatin on coronary events after MI in patients with average cholesterol levels.
        N Engl J Med. 1996; 335: 1001-1009
        • Post-Coronary Artery Bypass Graft Trial Investigators
        The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.
        N Engl J Med. 1997; 336: 153-162